Firstly, in recent research, Zhen et al. confirmed that CRISPR/Cas9 can inhibit the expression of long non-coding RNA UCA1, which acted as an oncogenic lncRNA in bladder cancer, to attenuate malignant phenotypes of bladder cancer [102]. Here, UCA1 is linked to urinary bladder cancer.